What was the primary driver behind the decrease in net income compared to the prior year's quarter?

The decrease in net income was primarily due to a significant charge of $53.3 million for acquired in-process research and development related to the acquisition of GeneOhm Sciences, Inc. This acquisition is expected to bolster BD's presence in the healthcare-associated infections market.

How did the GeneOhm acquisition impact the company's financial statements?

The GeneOhm acquisition, completed on February 14, 2006, resulted in an up-front cash payment of $230.4 million. It led to the recognition of $53.3 million in acquired in-process R&D expense, impacting net income. Goodwill of $78.8 million was recorded, primarily allocated to the Diagnostics segment.

What is the outlook for revenue growth and profit margins?

The company anticipates continued revenue growth driven by its core businesses, including the transition to safety-engineered devices and new product development across its segments. Management expects gross profit margin to improve by approximately 50 to 60 basis points in fiscal 2006, supported by increased sales of higher-margin products and cost-reduction initiatives.

How is the company managing rising raw material costs, specifically resin prices?

BD is experiencing higher resin purchase costs due to increased world oil prices. The company expects to mitigate this impact through continued profit margin improvement from higher-margin products, cost reduction programs, productivity enhancements, and periodic price adjustments.

BDX 10-Q Quarterly Report Q2 FY2006 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported its financial results for the quarter ending March 31, 2006. The company experienced a 6% increase in revenue compared to the prior year's quarter, reaching $1.45 billion. This growth was primarily driven by volume increases, although partially offset by unfavorable foreign currency translation. Net income for the quarter stood at $154 million, a decrease from the prior year's $188 million, largely impacted by a significant charge for acquired in-process research and development related to the GeneOhm acquisition. The company continues to focus on strategic initiatives to drive revenue growth and improve operating effectiveness, with key segments like BD Medical and BD Biosciences showing solid performance. Key financial highlights include a decrease in the debt-to-capitalization ratio, indicating improved balance sheet strength. The company also continued its share repurchase program, demonstrating a commitment to returning value to shareholders. While the company faces challenges such as increased resin purchase costs and foreign currency fluctuations, it maintains a positive outlook, expecting continued revenue growth and improved gross profit margins. Investors should note the impact of the GeneOhm acquisition and the associated R&D charge on current quarter earnings, as well as the ongoing strategic investments in new product development.

Key Highlights

1Revenue increased by 6% year-over-year to $1.45 billion for the quarter ended March 31, 2006.
2Net income decreased to $154 million from $188 million in the prior year, significantly impacted by a $53 million charge for acquired in-process R&D from the GeneOhm acquisition.
3The BD Medical segment showed strong revenue growth of 9%, driven by Diabetes Care and Pharmaceutical Systems.
4The BD Diagnostics segment saw modest revenue growth of 1%, impacted by a decline in Diagnostics Systems due to a milder flu season.
5The BD Biosciences segment grew revenue by 8%, with flow cytometry instruments and reagents being key contributors.
6The company's debt-to-capitalization ratio improved to 25.7% from 27.3% in the prior fiscal year.
7Share repurchases continued, with approximately $225 million spent in the first six months of the fiscal year.

BECTON DICKINSON & CO Quarterly Report for Q2 Ended Mar 31, 2006

Summary

Key Highlights

Frequently Asked Questions